Upadacitinib improved patient-reported pruritus in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial

被引：0
|
作者：
Hong, C. -H. [1 ]
Wu, T. [2 ]
Calimlim, B. [2 ]
Teixeira, H. [2 ]
de Bruin-Weller, M. [3 ]
机构：
[1] Univ British Columbia, Dept Dermatol & Skin Sci & Prob Med Res, Surrey, BC, Canada
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Med Ctr Utrecht, Utrecht, Netherlands
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Atopic dermatitis; Pruritus; Upadacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P011
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [41] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
  • [42] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61
  • [43] Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis: a phase III randomized, placebo-controlled trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E108 - E108
  • [44] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Reich, Kristian
    Kabashima, Kenji
    Igawa, Ken
    Suzuki, Tetsuya
    Mano, Hirotaka
    Matsui, Takeshi
    Esfandiari, Ehsanollah
    Furue, Masutaka
    [J]. LANCET, 2023, 401 (10372): : 204 - 214
  • [45] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
    Berth-Jones, J.
    Arkwright, P. D.
    Marasovic, D.
    Savani, N.
    Aldridge, C. R.
    Leech, S. N.
    Morgan, C.
    Clark, S. M.
    Ogilvie, S.
    Chopra, S.
    Harper, J. I.
    Smith, C. H.
    Rook, G. A. W.
    Friedmann, P. S.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1115 - 1121
  • [46] Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept
    Tyring, S.
    Bagel, J.
    Lynde, C.
    Klekotka, P.
    Thompson, E. H. Z.
    Gandra, S. R.
    Shi, Y.
    Kricorian, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (01) : 125 - 128
  • [47] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    [J]. LANCET, 2021, 397 (10290): : 2169 - 2181
  • [48] Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)
    Silverberg, Jonathan
    Eichenfield, Lawrence
    Blauvelt, Andrew
    Irvine, Alan D.
    Langley, Richard
    Guttman, Emma
    Warren, Richard
    French, Lars
    Pedersen, Claus Bang
    Carlsson, Anna
    Jensen, Morten Lind
    Sommer, Morten O. A.
    Kjoller, Kim
    Simpson, Eric
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 68 - 69
  • [49] Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Pavel, A.
    Estrada, Y.
    Zhang, N.
    Peng, X.
    Xu, H.
    Wen, H.
    Fang, H.
    Salhi, Y.
    Gudi, G.
    Ca, V.
    Gn, S.
    Grossman, F.
    Wolff, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E45
  • [50] Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
    Simpson, Eric L.
    Gadkari, Abhijit
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) : 506 - 515
12345